Evaluation of Serum miRNA as a Diagnostic Tool for Canine Splenic Hemangiosarcoma
Hemangiosarcoma (HSA) is the most common tumor of the spleen in dogs and is associated with short survival times and high mortality. Currently, HSA cannot be differentiated from other masses of the spleen (which often have improved prognoses) without surgical excision of the tumor. In dogs with splenic masses, knowledge of the underlying disease process would help owners to make a more informed decision on pursuing treatment for their pet. Another concern is that most dogs with HSA are diagnosed late in their disease course. Dogs with lower stage disease have better survival than dogs with higher stage disease, thus development of a sensitive diagnostic test for HSA would allow for pre-screening, which would identify the presence of a tumor earlier than is currently possible, allowing for improved outcomes.
Dogs must present to the University of Georgia Veterinary Teaching Hospital for surgical removal of a splenic mass. This includes any breed of dog with a splenic mass, commonly Golden Retrievers, Labrador Retrievers, German Shepherd Dogs, and many other breeds.
Blood sample before surgery
Blood sample 24-48 hours after surgery
Blood sample 2-3 weeks after surgery
Name: Lisa Reno, Clinical Trials Coordinator
Principal Investigator: Janet A. Grimes, DVM, MS, DACVS-SA
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.